|
 |
OxandrinThis page contains recent news articles, when available, and an overview of Oxandrin but does not offer medical advice. You should contact your physician with regard to any health issues or concerns....manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the US Puricase is a registered trademark of Mountain View Pharmaceuticals, Inc. CNNMoney.com (press release) Savient Pharmaceuticals Inc (SVNT) VP, CFO David Gionco sells 1511 Shares - Dec 22, 2009 Products marketed by Savient's sales force in the United States are Oxandrin (oxandrolone, USP) and Delatestryl (testosterone enanthate). ... GuruFocus.com Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results - Nov 4, 2009 Additionally, we adjusted our Oxandrin product return reserve in both the current and prior year quarters to reflect higher actual return experience. ... Reuters Savient Pharmaceuticals Inc Reports Operating Results (10-Q) - Nov 9, 2009 Products marketed by Savient's sales force in the United States are Oxandrin (oxandrolone, USP) and Delatestryl (testosterone enanthate). ... GuruFocus.com Savient Pharmaceuticals to Present at the Oppenheimer 20th Annual Healthcare ... - Oct 27, 2009 ...from Duke University and Mountain View Pharmaceuticals, Inc. Savient also manufactures and supplies Oxandrin(R) (oxandrolone tablets, USP) CIII in the ... Reuters Savient Pharmaceuticals to Hold Third Quarter 2009 Financial Results ... - Oct 28, 2009 ...from Duke University and Mountain View Pharmaceuticals, Inc. Savient also manufactures and supplies Oxandrin(R) (oxandrolone tablets, USP) CIII in the ... Reuters Savient Pharmaceuticals Inc - SWOT Analysis - Oct 24, 2009 The decrease was primarily attributable to lower product sales of Oxandrin as a result of generic competition. The operating loss of the company was $69 ... PRMinds (press release) Savient restraining order vs Novartis, others lifted in Oxandrin gener... - Dec 11, 2006 ZURICH (AFX) - US drug maker Savient Pharmaceuticals Inc said a temporary restraining order blocking the sale of all generic versions of its Oxandrin drug ... Forbes Savient Cites Court Win | Biotech News | Print Financial & Investing ... - Dec 5, 2006 ...infringement of a number of patents on the company's anabolic drug Oxandrin, which is used ... but it will continue to market its Oxandrin branded drug. ... TheStreet.com - TheStreet.com (subscription) Barr Confirms Patent Challenge of Oxandrin(R) Tablets, 2.5 mg and 10 ... - Sep 26, 2006 WOODCLIFF LAKE, NJ, Sept. 26 /PRNewswire-FirstCall/ -- Barr Laboratories, Inc., a subsidiary of Barr Pharmaceuticals, Inc. (NYSE: BRL), today confirmed that ... Genetic Engineering News - Genetic Engineering News (press release) … Announces Launch of Authorized Generic of Oxandrin(R) with Watson ... - Dec 29, 2006 Oxandrin([R])is Savient's oral anabolic agent for the treatment of ... Savient will continue to market and distribute the Oxandrin([R]) brand product. ... Free with registration - Business Wire - AccessMyLibrary.com … Pharmaceuticals Files Citizens' Petition With the FDA for Oxandrin(... - Sep 21, 2005 A significant number of patients who are treated with Oxandrin(R) are geriatric ... Oxandrin(R) is an oral tablet, which contains oxandrolone, indicated as ... RedOrbit Savient Pharmaceuticals Declines Most Since 2002 - Sep 26, 2008 Savient sells Oxandrin, a therapy used to promote weight gain after extensive surgery. Savient slumped $2.90, or 15 percent, to $15.82 at 4 pm New York time ... Bloomberg Savient Pharmaceuticals to Present at 28th Annual Cowen - Mar 12, 2008 Savient also manufactures and supplies Oxandrin(R) (oxandrolone tablets, USP) CIII in the US Puricase is a registered trademark of Mountain View ... Bloomberg Savient: Court temporarily enjoins generic Oxandrin launch. - Dec 12, 2006 SAN FRANCISCO (MarketWatch) -- Savient Pharmaceuticals Inc. late Tuesday said the US Court of Appeals for the Federal Circuit in Washington has issued an ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Savient Pharmaceuticals Reports Third Quarter and Year-to-Date 2007 … - Oct 31, 2007 This decrease was primarily due to a reduction in Oxandrin promotional ... Product sales of Oxandrin were lower by $31.6 million offset partially by ... Free with registration - Business Wire - AccessMyLibrary.com Savient Pharmaceuticals Reports Unaudited Results for First Quarter … - Mar 31, 2005 Net sales of Oxandrin in the first quarter were $8.3 million compared to $18.4 ... Total prescriptions for Oxandrin declined 7% versus a year ago and 6% ... businesswire.com Savient Pharmaceuticals Reports Second Quarter and Year-to-Date 2007 … - Jul 31, 2007 This decrease was primarily due to a reduction in Oxandrin promotional activities and termination of our Oxandrin sales force in the beginning of 2007 due ... Genetic Engineering News - Genetic Engineering News (press release) Barr Confirms Patent Challenge of Oxandrin(R) Tablets, 2.5 mg and 10 ... - Sep 26, 2006 WOODCLIFF LAKE, NJ, Sept. 26 /PRNewswire-FirstCall/ -- Barr Laboratories, Inc., a subsidiary of Barr Pharmaceuticals, Inc. , today confirmed that it is ... Free with registration - PR Newswire - AccessMyLibrary.com Savient Announces Completion Of Patient Enrollment In Phase 3 Trials... - Mar 13, 2007 Savient also markets Oxandrin®, oxandrolone tablets, (USP) C III in the US Puricase is a registered trademark of Mountain View Pharmaceuticals, Inc. Further ... Medical News Today - Medical News Today (press release) Savient Pharmaceuticals Reports First Quarter 2007 Financial Results - May 7, 2007 In 2007, the revenues from Oxandrin include both the sales of branded Oxandrin and the revenues from the distribution agreement for generic oxandrolone ... Genetic Engineering News - Genetic Engineering News (press release) Savient Pharmaceuticals, Inc. Corrects Method of Recognizing Revenue ... - Jan 6, 2005 Products marketed by Savient in the United States are Oxandrin(R) (oxandrolone, USP) and Delatestryl(R) (testosterone enanthate). ... Free with registration - Business Wire - AccessMyLibrary.com Savient and Teva Launch TEV-TROPIN for Pediatric Growth Hormone … - Feb 11, 2005 Products marketed by Savient in the United States are Oxandrin(R) (oxandrolone, USP) and Delatestryl(R) (testosterone enanthate). The Company's subsidiary ... Free with registration - Business Wire - AccessMyLibrary.com ALLIANT TECH SAYS $500M ARMY PROGRAM AT RISK - Dec 6, 2006 Savient, based in East Brunswick, NJ, sued the companies Monday, claiming their copies of Oxandrin would infringe five Savient patents. ... $2.95 - St. Paul Pioneer Press - NewsBank Savient Pharmaceuticals to Hold Third Quarter 2008 Financial Results ... - Nov 6, 2008 Savient also manufactures and supplies Oxandrin(R) (oxandrolone tablets, USP) CIII in the US Puricase is a registered trademark of Mountain View ... International Business Times Savient Pharma swings to 4Q loss - Mar 14, 2007 Savient Pharmaceuticals said its Oxandrin product for the treatment of weight ... The company launched an authorized generic version of Oxandrin through a ... ABCmoney.co.uk Savient Pharmaceuticals to Provide Business Update on November 7, … - Nov 7, 2005 ...introduction of generic competition for Oxandrin(R); fluctuations in ... potential future returns of Oxandrin or other products; our continuing to incur ... RedOrbit Savient Pharmaceuticals Reports Second Quarter and First Half 2006 … - Aug 9, 2006 Sales of Oxandrin were $13.8 million for the second quarter of 2006 compared ... The higher sales of Oxandrin and oral liquid pharmaceutical products were ... businesswire.com Following Launch of Authorized Generic. - Jan 8, 2007 Oxandrin is Savient's oral anabolic agent for the treatment of involuntary weight loss, a frequent and sometimes life-threatening condition associated with ... $4.95 - M2 Presswire - ECNext Savient petititons FDA to extend Oxandrin exclusivity.(Brief Article) - Oct 3, 2005 Savient Pharmaceuticals, an emerging USA-based specialty drugmaker, has filed a Citizens' Petition with the Food and Drug Administration requesting that it ... $4.95 - Pharma Marketletter - ECNext Wall Street's Wish List - Jan 29, 2007 This week, let's meet Savient, the small pharmaceutical company best known for its Oxandrin, a testosterone derivative used to promote weight gain in ... fool.com Savient Pharmaceuticals to Sell Global Biologics Manufacturing... - Mar 23, 2005 Products marketed by Savient in the United States are Oxandrin(R) (oxandrolone, USP) and Delatestryl(R) (testosterone enanthate). The Company's subsidiary ... $4.95 - Business Wire - ECNext Savient Pharmaceuticals, Inc. Announces Exploration of Strategic … - Feb 17, 2006 Savient markets its product Oxandrin(R) (oxandrolone, USP) in the United States. The Company's subsidiary, Rosemont Pharmaceuticals Ltd., develops, ... RedOrbit Savient Pharma Rises on Citi Comments - Nov 28, 2007 East Brunswick, NJ-based Savient makes Oxandrin, which treats involuntary weight loss caused by trauma, surgery or diseases such as HIV. ... fool.com Savient Pharmaceuticals Initiates Patient Dosing for Puricase(R)... - Jun 14, 2006 Savient markets its product Oxandrin(R) (oxandrolone, USP) in the United States. The Company's subsidiary, Rosemont Pharmaceuticals Ltd., develops, ... RedOrbit Savient Pharmaceuticals Closes Sale of Global Biologics Manufacturing... - Jul 18, 2005 Products marketed by Savient in the United States are Oxandrin(R) (oxandrolone, USP) and Delatestryl(R) (testosterone enanthate). The Company's subsidiary ... $4.95 - Business Wire - ECNext Savient Pharmaceuticals to Report Full Year 2005 Financial Results on... - Mar 30, 2006 Savient markets its product Oxandrin(R) (oxandrolone, USP) in the United States. The Company's subsidiary, Rosemont Pharmaceuticals Ltd., develops, ... businesswire.com … Release: Barr Confirms Patent Challenge of Oxandrin(R) Tablets,... - Sep 26, 2006 Barr Confirms Patent Challenge of Oxandrin(R) Tablets, 2.5 mg and 10 mg. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Savient Pharmaceuticals Restructures Commercial Operations Following ... - Jan 5, 2007 Oxandrin(R) is Savient's oral anabolic agent for the treatment of involuntary weight loss, a frequent and sometimes life-threatening condition associated ... Genetic Engineering News - Genetic Engineering News (press release) Savient Pharmaceuticals to Report First Quarter 2006 Financial... - May 11, 2006 Savient markets its product Oxandrin(R) (oxandrolone, USP) in the United States. The Company's subsidiary, Rosemont Pharmaceuticals Ltd., develops, ... businesswire.com Savient Pharmaceuticals to Report Second Quarter 2006 Financial … - Aug 2, 2006 Savient markets its product Oxandrin(R) (oxandrolone, USP) in the United States. The Company's subsidiary, Rosemont Pharmaceuticals Ltd., develops, ... Free with registration - Business Wire - AccessMyLibrary.com Press Release: Following Launch of Authorized Generic. - M2 Presswire... - Jan 8, 2007 29122006 Savient Pharma Reveals Launch Of Authorized Generic Of Oxandrin . ... "Early in the quarter ... revenues from Oxandrin and our authorized generic ... Pay-Per-View - M2 Presswire - HighBeam Research Bloomberg Printer-Friendly Page - May 8, 2008 The lower revenues reflect the continued impact of generic competition on sales of Oxandrin(R) (oxandrolone tablets, USP) CIII to promote weight gain ... Bloomberg Savient restructures following generic appro.(Savient Pharmaceuticals... - Jan 15, 2007 New Jersey, USA-based Savient Pharmaceuticals says that, following the launch of its AB rated authorized generic of oxandrolone tablets, an Oxandrin brand ... $4.95 - Pharma Marketletter - ECNext Savient Pharmaceuticals Obtains TRO in Patent Infringement Lawsuit - Jun 12, 2006 Oxandrin is Savient's oral anabolic agent indicated as adjunctive therapy to promote ... Oxandrin is also indicated for patients who, without definite ... ag-IP-news Agency AIDS activists upset by dropped wasting drug - Apr 19, 2007 Their suspicions grew through this week as they learned that Savient Pharmaceuticals canceled its patient assistance program for Oxandrin, the second most ... Bay Area Reporter Savient Pharmaceuticals Files Patent Infringement Lawsuit Against... - May 12, 2006 According to a press release by the company, these patents relate to various methods of using Savient's product Oxandrin (oxandrolone tablets, USP) CIII. ... ag-IP-news Agency Savient Pharmaceuticals Reports Unaudited Results for Second Quarter ... - Aug 9, 2005 ...--Net sales of Oxandrin in the second quarter were $12.5 million compared to ... --Net sales of Oxandrin were $22.3 million compared to $18.5 million a year ... $4.95 - Business Wire - ECNext Savient Pharmaceuticals Inc - Company Snapshot - AlacraStore.com - Oct 8, 2008 The Group products are Oxandrin & oxandrolone .Oxandrin is an oral synthetic derivative of testosterone used to promote weight gain following involuntary ... Pay-Per-View - co - Alacra Store Press Release: Current Research on Savient Pharmaceuticals Inc. - M2 ... - Jan 8, 2007 Savient will focus on selling its remaining drugs, including top seller Oxandrin, which treats involuntary weight loss due to trauma, surgery, ... Pay-Per-View - M2 Presswire - HighBeam Research Savient Pharmaceuticals Reports Third Quarter Financial Results - Oct 30, 2006 US sales of Oxandrin, the Company's product for the treatment of weight gain following involuntary weight loss related to disease or medical condition, ... Genetic Engineering News - Genetic Engineering News (press release) FINAL TRANSCRIPT - May 8, 2008 The sales of Oxandrin and oxandrolone are becoming less significant to our overall ... This increase was primarily due to $1.2 million of higher Oxandrin ... $54.00 - Thomson StreetEvents - Alacra Store Savient Pharmaceuticals to Report First Quarter Financial Results on... - May 10, 2005 Products marketed by Savient in the United States are Oxandrin(R) (oxandrolone, USP) and Delatestryl(R) (testosterone enanthate). The Company's subsidiary ... businesswire.com Patient Dosing in Phase 2 Clinical Trial of Puricase for Severe Gout ... - Jan 12, 2005 Products marketed by Savient in the United States are Oxandrin(R) (oxandrolone, USP) and Delatestryl(R) (testosterone enanthate). ... Medical News Today - Medical News Today (press release) California Courts of Appeal Reports - SAVIENT PHAR. v. DEPT. OF HE. … - Jan 23, 2007 Savient makes Oxandrin, a drug used to treat weight loss. ... We refer to this as a delisting, although Oxandrin remains listed for some uses. ... Pay-Per-View - California Courts of Appeal Reports - Loislaw Savient Pharmaceuticals to Report Fourth Quarter and Full Year 2004 … - Mar 16, 2005 Products marketed by Savient in the United States are Oxandrin(R) (oxandrolone, USP) and Delatestryl(R) (testosterone enanthate). The Company's subsidiary ... businesswire.com Savient Pharmaceuticals, Inc. Establishes Science and Development … - Jan 26, 2005 Products marketed by Savient in the United States are Oxandrin(R) (oxandrolone, USP) and Delatestryl(R) (testosterone enanthate). The Company's subsidiary ... TMC Net Short Trader: Savient Bulls Take Their Medicine - Mar 27, 2007 Two of the company's main drugs are Oxandrin and Puricase. Oxandrin is used to promote weight gain following involuntary weight loss related to medical ... TheStreet.com - TheStreet.com (subscription) Savient Pharmaceuticals Joins Russell 3000 and New Russell Microcap … - Jun 27, 2005 Products marketed by Savient in the United States are Oxandrin(R) (oxandrolone, USP) and Delatestryl(R) (testosterone enanthate). The Company's subsidiary ... $4.95 - Business Wire - ECNext Tuesday's Health Winners & Losers - Dec 5, 2006 Cramer's Take) subsidiary Sandoz Pharmaceuticals and Upsher-Smith Laboratories for infringing a on number of patents on its weight-gain drug Oxandrin. ... TheStreet.com - TheStreet.com (subscription) Savient Receives FDA Final Approval for Puricase (PEG-uricase) Phase... - May 3, 2006 Savient markets its product Oxandrin(R) (oxandrolone, USP) in the United States. The Company's subsidiary, Rosemont Pharmaceuticals Ltd., develops, ... Free with registration - Business Wire - AccessMyLibrary.com Four Abstracts Accepted for Savient's Puricase(R) at European League ... - Apr 19, 2006 Savient markets its product Oxandrin(R) (oxandrolone, USP) in the United States. The Company's subsidiary, Rosemont Pharmaceuticals Ltd., develops, ... RedOrbit Savient Pharmaceuticals, Inc. Files Universal Shelf Registration … - Sep 24, 2007 Savient also manufactures and supplies Oxandrin([R]) (oxandrolone tablets, USP) CIII in the US Puricase is a registered trademark of Mountain View ... Free with registration - Business Wire - AccessMyLibrary.com Savient Pharmaceuticals Announces Official Support of the American … - Nov 3, 2006 Savient also markets Oxandrin(R) (oxandrolone tablets, USP) CIII in the US Puricase is a registered trademark of Mountain View Pharmaceuticals, Inc. Further ... Free with registration - PR Newswire - AccessMyLibrary.com Savient Seems Set for a Success - May 22, 2007 Puricase would join Savient's Oxandrin -- which combats severe weight loss caused by infection, surgery or trauma -- on the market. ... fool.com Savient Pharmaceuticals Completes Puricase Phase 3 Studies For … - Oct 19, 2007 Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the US Puricase is a registered trademark of Mountain View ... Medical News Today - Medical News Today (press release) Savient Pharmaceuticals to Report Full Year 2005 Financial Results on... - Mar 28, 2006 Savient markets its product Oxandrin(R) (oxandrolone, USP) in the United States. The Company's subsidiary, Rosemont Pharmaceuticals Ltd., develops, ... Free with registration - Business Wire - AccessMyLibrary.com Savient Pharmaceuticals Closes Sale of Delatestryl(R) Product to... - Jan 9, 2006 Savient markets its product Oxandrin(R) (oxandrolone, USP) in the United States. The Company's subsidiary, Rosemont Pharmaceuticals Limited, develops, ... RedOrbit ×¡×‘×™×™× ×˜ זכתה בצו ×ž× ×™×¢×” למכירת גרסות ×’× ×¨×™×•×ª לתרופתה - Dec 13, 2006 ...תרופת ×”-Oxandrin שלה. צו ×”×ž× ×™×¢×” בה בהמשך לבקשת ... ×”-Oxandrin ×”×™× ×” תרופה של ×¡×‘×™×™× ×˜, ×?שר × ×™×ª× ×ª ... Bizportal Savient Pharmaceuticals, Inc. to Present at the Banc of America... - Jul 25, 2005 Products marketed by Savient in the United States are Oxandrin(R) (oxandrolone, USP) and Delatestryl(R) (testosterone enanthate). The Company's subsidiary ... $4.95 - Business Wire - ECNext Savient Provides Update on Form 10-K Filing Date. - Mar 15, 2006 Savient markets its product Oxandrin(R) (oxandrolone, USP) in the United States. The Company's subsidiary, Rosemont Pharmaceuticals Ltd., develops, ... $4.95 - Business Wire - ECNext Savient Pharmaceuticals, Inc. to Present at the UBS 2005 Global Life ... - May 20, 2005 Products marketed by Savient in the United States are Oxandrin(R) (oxandrolone, USP) and Delatestryl(R) (testosterone enanthate). The Company's subsidiary ... $4.95 - Business Wire - ECNext Savient Pharmaceuticals to Report Second Quarter Unaudited Results on... - Aug 1, 2005 Products marketed by Savient in the United States are Oxandrin(R) (oxandrolone, USP) and Delatestryl(R) (testosterone enanthate). The Company's subsidiary ... $4.95 - Business Wire - ECNext Savient Pharmaceuticals Meets with FDA for End-of-Phase 2 Review of … - Jul 28, 2005 Products marketed by Savient in the United States are Oxandrin(R) (oxandrolone, USP) and Delatestryl(R) (testosterone enanthate). The Company's subsidiary ... $4.95 - Business Wire - ECNext Savient Terminating Phase 2 Trial for Prosaptide; Dose Ranging Study ... - Mar 11, 2005 Products marketed by Savient in the United States are Oxandrin(R) (oxandrolone, USP) and Delatestryl(R) (testosterone enanthate). The Company's subsidiary ... $4.95 - Business Wire - ECNext Loislaw Federal District Court Opinions - IN RE BIO-TECHNOLOGY … - Oct 26, 2006 Second, Plaintiff claimed that BTG and its management falsely attributed the source of a sharp increase in sales of its premier drug product, Oxandrin, ... Pay-Per-View - Loislaw Federal District Court Opinions - Loislaw Savient Pharmaceuticals to Report Fourth Quarter and Full Year 2004 … - Mar 8, 2005 Products marketed by Savient in the United States are Oxandrin(R) (oxandrolone, USP) and Delatestryl(R) (testosterone enanthate). The Company's subsidiary ... $4.95 - Business Wire - ECNext Loislaw Federal District Court Opinions - IN RE BIO-TECHNOLOGY … - Aug 10, 2005 Second, Plaintiff claims that BTG and its management falsely attributed the source of a sharp increase in sales of its premier drug product, Oxandrin, ... Pay-Per-View - Loislaw Federal District Court Opinions - Loislaw Savient files patent suit against Sandoz. - Dec 22, 2006 Oxandrin is also indicated for patients who, without definite pathophysiologic reason, fail to gain or maintain normal weight, and can be used to offset the ... $9.94 - Pharma Marketletter - Alacra Store Savient Pharmaceuticals Commences Offer to Repurchase up to 10 … - Aug 14, 2006 ...drug candidate currently in phase 3 clinical trials for treatment-failure gout, and the possible timing and effect of a generic version of Oxandrin(R)." ... $4.95 - Business Wire - ECNext Savient Pharmaceuticals, Inc. Announces Results of 2005 Annual … - Jun 1, 2005 Products marketed by Savient in the United States are Oxandrin(R) (oxandrolone, USP) and Delatestryl(R) (testosterone enanthate). The Company's subsidiary ... $4.95 - Business Wire - ECNext Savient Pharmaceuticals, Inc. To Webcast Annual Meeting of … - May 31, 2005 Products marketed by Savient in the United States are Oxandrin(R) (oxandrolone, USP) and Delatestryl(R) (testosterone enanthate). The Company's subsidiary ... $4.95 - Business Wire - ECNext Savient Pharmaceuticals Inc. Announces Partial Settlement of Human … - Feb 1, 2005 Products marketed by Savient in the United States are Oxandrin(R) (oxandrolone, USP) and Delatestryl(R) (testosterone enanthate). ... $4.95 - Business Wire - ECNext Savient Pharmaceuticals, Inc. Provides Update on Closing of Sale of … - Jun 24, 2005 Products marketed by Savient in the United States are Oxandrin(R) (oxandrolone, USP) and Delatestryl(R) (testosterone enanthate). The Company's subsidiary ... $4.95 - Business Wire - ECNext Savient Pharmaceuticals to Report First Quarter Financial Results on... - May 2, 2005 Products marketed by Savient in the United States are Oxandrin(R) (oxandrolone, USP) and Delatestryl(R) (testosterone enanthate). The Company's subsidiary ... $4.95 - Business Wire - ECNext Monday's biggest stock gainers and decliners. - Jan 8, 2007 The move follows the company's launch of oxandrolone, the generic version of Oxandrin. Scopus Video Networks Ltd. shares rose 7.5% after the Israel-based ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Bloomberg Printer-Friendly Page - Jun 9, 2008 Savient also manufactures and supplies Oxandrin(r) (oxandrolone tablets, USP) CIII in the US Puricase is a registered trademark of Mountain View ... Bloomberg Savient Pharmaceuticals Announces CFO Management Change - Oct 5, 2005 ...introduction of generic competition for Oxandrin; fluctuations in buying ... potential future returns of Oxandrin or other products; our continuing to ... RedOrbit Savient to Host Conference Call on Pegloticase Scientific - Oct 14, 2008 Savient also manufactures and supplies Oxandrin(r) (oxandrolone tablets, USP) CIII in the US Puricase is a registered trademark of Mountain View ... Bloomberg Savient Pharmaceuticals, Inc. to Present at the Roth Capital Partners... - Sep 2, 2005 ...introduction of generic competition for Oxandrin; fluctuations in buying ... potential future returns of Oxandrin or other products; our continuing to ... $4.95 - Business Wire - ECNext Savient Receives Nasdaq Delisting Notice Related to Late Form 10-Q. - Aug 19, 2005 ...introduction of generic competition for Oxandrin; fluctuations in buying ... potential future returns of Oxandrin or other products; our continuing to ... $4.95 - Business Wire - ECNext Savient Audit Committee Completes Review. - Oct 14, 2005 ...introduction of generic competition for Oxandrin(R); fluctuations in ... potential future returns of Oxandrin or other products; our continuing to incur ... $4.95 - Business Wire - ECNext Savient seeks European partner for first breakthrough gout treatment... - Jul 10, 2006 Sales of Oxandrin in the USA were $60.0 million last year and Rosemount produced $40.0 million, said Mr Clement. The company already has a sales force of 20 ... $9.94 - Pharma Marketletter - Alacra Store Other News To Note. - Sep 27, 2006 Oxandrin can also be used to offset the protein catabolism associated with prolonged corticosteroid use. Scolr Pharma Inc., of Bellevue, Wash., ... Pay-Per-View - BIOWORLD Today - Factiva, from Dow Jones Savient Pharmaceuticals Reports Unaudited Results for the Fourth … - Mar 16, 2005 ...--Net sales of Oxandrin(R), Savient's largest selling brand, in the fourth quarter were $15.2 million up ... "Oxandrin remains without generic competition. ... $4.95 - Business Wire - ECNext Savient Shareholder Class Action Suit Dismissed. - Aug 15, 2005 ...introduction of generic competition for Oxandrin; fluctuations in buying ... potential future returns of Oxandrin or other products; our continuing to ... $4.95 - Business Wire - ECNext First-time generic approvals.(FDA Drug Approvals)(Brief article) - Jan 1, 2007 Oxandrolone tablets, 2.5 mg (equiv to Oxandrin tablets, 2.5 mg) UPSHER-SMITH, SANDOZ Oxandrolone tablets, 10 mg (equiv to Oxandrin tablets, 10 mg) SANDOZ ... $4.95 - Formulary - ECNext FDA first-time generics approvals--2006.(Special Report)(Statistical... - Feb 19, 2007 ...and 300 g DECEMBER Oxandrolone tablets Upsher-Smith Oxandrin tablets USP, 2.5 mg Laboratories Inc. Oxandrolone tablets Sandoz Inc. Oxandrin tablets USP, ... Pay-Per-View - Chain Drug Review - HighBeam Research Article: The Washington, DC, court of appeals has affirmed a lower... - Aug 1, 2005 Pharmaceuticals Reveals Launch Of Authorized Generic Of Oxandrin With Watson Pharmaceuticals ... Savient Pharma Reveals Launch Of Authorized Generic Of ... Pay-Per-View - Medical Marketing & Media - HighBeam Research Two Abstracts Highlighting Savient Pharmaceuticals' Puricase(R) … - Oct 3, 2005 ...introduction of generic competition for Oxandrin; fluctuations in buying ... potential future returns of Oxandrin or other products; our continuing to ... $4.95 - Business Wire - ECNext Savient Pharmaceuticals, Inc. Announces Second Amended Complaint in … - Oct 21, 2005 ...introduction of generic competition for Oxandrin; fluctuations in buying ... potential future returns of Oxandrin or other products; our continuing to ... $4.95 - Business Wire - ECNext Savient Pharmaceuticals to Present at the 27th Annual JP - Dec 8, 2008 Savient also manufactures and supplies Oxandrin(R) (oxandrolone tablets, USP) CIII in the US Puricase is a registered trademark of Mountain View ... Bloomberg Savient Pharmaceuticals to Hold Third Quarter 2008 Financial - Oct 24, 2008 Savient also manufactures and supplies Oxandrin(R) (oxandrolone tablets, USP) CIII in the US Puricase is a registered trademark of Mountain View ... Bloomberg Savient Pharmaceuticals to Present At Citi Investment Research G - May 13, 2008 Savient also manufactures and supplies Oxandrin(r) (oxandrolone tablets, USP) CIII in the US Puricase is a registered trademark of Mountain View ... Bloomberg Savient to Present at the 2008 Merrill Lynch Global - Jan 22, 2008 Savient also manufactures and supplies Oxandrin(R) (oxandrolone tablets, USP) CIII in the US Puricase is a registered trademark of Mountain View ... Bloomberg ביו×? שישי בחר, גורו ×”×ž× ×™×•×ª, ×’'×™×? קרמר בחברת ×¡×‘×™×™× ×˜ כבחירה השל - Jan 8, 2007 ...שישי ×”×?חרון, חברת ×¡×‘×™×™× ×˜ הודיעה שהי×? מפסיקה ×?ת צוות המכירה שלה לשיווק תרופת ×”-Oxandrin, ... Bizportal Stocks expected to move Wednesday - MarketWatch - Dec 12, 2006 Savient Pharmaceuticals Inc. said a federal appellate court in Washington, DC, has temporarily banned all sales of generic Oxandrin, a weight treatment, ... MarketWatch |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |